Navigation Links
Cancer signatures uncovered
Date:8/15/2008

A new systematic analysis of the relationship between the neoplastic and developmental transcriptome provides an outline of trends in cancer gene expression. The research, published recently in BioMed Central's open access journal Genome Biology, describes how cancers can be divided into three groups distinguished by disparate developmental signatures.

Isaac S Kohane from Children's Hospital Boston and Harvard University, US, led a team of researchers who performed a comprehensive comparison of genes expressed in early developmental stages of various human tissues and those expressed in different cancers affecting these tissues. He says, "Our study reveals potentially clinically relevant differences in the gene expression of different cancer types and represents a reference framework for interpretation of smaller-scale functional studies".

One of the three described groups of cancers has an early developmental phenotype and expresses genes that are characteristic of stem cells. From a developmental perspective, this group presents very homogeneously. A second, more heterogeneous group tends to be more similar to late development and is characterized by an inflammatory signature. The third is a small group of cancers that present as a transition phenotype between these two extremes and displays both characteristics.

According to Kohane, "This segregation of tumors into three groups with distinct expression patterns is surprising. Clearly, the developmental trajectory provides a meaningful background for capturing large-scale differences in gene expression across diverse conditions".

The study's results will lead towards a better understanding of human disease from a 'macrobiological' approach to analyzing high-throughput data. According to the authors, "Shifting our focus from single sets of genes or processes to the biology of aggregates on the order of the entire transcriptome is likely to be useful in establishing highly robust molecular correlations between seemingly unrelated disease phenotypes".


'/>"/>
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-707-94804
BioMed Central
Source:Eurekalert

Related biology news :

1. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
2. Scientists discover major genetic cause of colorectal cancer
3. Commercialization aim of grant supporting technology that destroys cancer cells
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. Monash researchers uncover cancer survival secrets
6. Researchers find cancer-inhibiting compound under the sea
7. Pre-cancerous condition linked to chronic acid reflux faces several hurdles
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
10. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
11. A new cellular pathway linked to cancer is identified by NYU researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which ... it has submitted a 510(k) to the FDA, requesting clearance of the MyoCycle ... electrical stimulation (FES) technology. , The submission marks a major milestone for ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... report the publishing of the latest paper by its Science Editor, Dr. Elisabeth ... (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from ...
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
Breaking Biology Technology: